June 22, 2020 | Video
David E. Anderson, Ph.D., discusses updated Part B data from the VBI's ongoing Phase 1/2a study of VBI-1901, the company’s cancer vaccine immunotherapeutic, with Allen Waziri, M.D., CEO and Co-Founder, iCE Neurosystems, Former Director of the Brain Tumor Program at Inova Neuroscience Institute, and member of VBI’s GBM/Immuno-Oncology Scientific and Clinical Advisory Board.
Discussion of Data Presented at Society for Neuro-Oncology (SNO) 2020 Annual Meeting
Date: November 19, 2020
Presenters: Jeff Baxter, VBI CEO, and Dr. David E. Anderson, Ph.D., VBI CSO
Date: October 27, 2016
Presenters: Dr. Daniel Shouval, M.D., and Dr. Florian Schödel, M.D.
Date: October 26, 2016
Presenters: Dr. David E. Anderson, VBI CSO
Date: October 25, 2016
Presenters: Dr. David E. Anderson, VBI CSO
Date: October 25, 2016
Presenters: Jeff Baxter, VBI CEO
Date: October 25, 2016
Presenters: Dr. David E. Anderson, VBI CSO
Date: October 15, 2016
Presenters: Dr. Daniel Shouval, M.D., and Dr. Florian Schödel, M.D.
Date: August 15, 2014
Presenters: Dr. David E. Anderson, VBI CSO
Date: August 5, 2014
Presenters: Dr. David E. Anderson, VBI CSO
